DNA repair capacity is impaired in healthy BRCA1 heterozygous mutation carriers

Published on Jul 1, 2015in Breast Cancer Research and Treatment3.471
· DOI :10.1007/s10549-015-3459-3
Tereza Vaclova3
Estimated H-index: 3
Gonzalo Gómez-López30
Estimated H-index: 30
+ 7 AuthorsAna Osorio43
Estimated H-index: 43
BRCA1 germline mutations increase the lifetime risk of developing breast and ovarian cancers. However, taking into account the differences in disease manifestation among mutation carriers, it is probable that different BRCA1 mutations have distinct haploinsufficiency effects and lead to the formation of different phenotypes. Using lymphoblastoid cell lines derived from heterozygous BRCA1 mutation carriers and non-carriers, we investigated the haploinsufficiency effects of various mutation types using qPCR, immunofluorescence, and microarray technology. Lymphoblastoid cell lines carrying a truncating mutation showed significantly lower BRCA1 mRNA and protein levels and higher levels of gamma-H2AX than control cells or those harboring a missense mutation, indicating greater spontaneous DNA damage. Cells carrying either BRCA1 mutation type showed impaired RAD51 foci formation, suggesting defective repair in mutated cells. Moreover, compared to controls, cell lines carrying missense mutations displayed a more distinct expression profile than cells with truncating mutations, which is consistent with different mutations giving rise to distinct phenotypes. Alterations in the immune response pathway in cells harboring missense mutations point to possible mechanisms of breast cancer initiation in carriers of these mutations. Our findings offer insight into how various heterozygous mutations in BRCA1 could lead to impairment of BRCA1 function and provide strong evidence of haploinsufficiency in BRCA1 mutation carriers.
  • References (36)
  • Citations (15)
📖 Papers frequently viewed together
29 Citations
14 Authors (Hannah Farmer, ..., Alan Ashworth)
3,482 Citations
43 Citations
78% of Scinapse members use related papers. After signing in, all features are FREE.
#1Francesca GrassoH-Index: 3
#2Elisa GiacominiH-Index: 3
Last. Margherita BignamiH-Index: 38
view all 9 authors...
The MUTYH DNA glycosylase counteracts mutagenesis by removing adenine misincorporated opposite DNA 8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG). Biallelic germline mutations in MUTYH cause the autosomal recessive MUTYH-associated polyposis (MAP). The impact on genetic instability of the p.Tyr179Cys and p.Arg245His MUTYH variants was evaluated in lymphoblastoid cell lines (LCLs) derived from MAP patients and their relatives in comparison to wild-type LCLs. No difference in MUTYH expression was i...
8 CitationsSource
#1Harriet Feilotter (Queen's University)H-Index: 17
#2Claire Michel (Queen's University)H-Index: 1
Last. Scott Davey (Queen's University)H-Index: 15
view all 5 authors...
The assessment of BRCA1 and BRCA2 coding sequences to identify pathogenic mutations associated with inherited breast/ovarian cancer syndrome has provided a method to identify high-risk individuals, allowing them to seek preventative treatments and strategies. However, the current test is expensive, and cannot differentiate between pathogenic variants and those that may be benign. Focusing only on one of the two BRCA partners, we have developed a biological assay for haploinsufficiency of BRCA1. ...
7 CitationsSource
#1Anthony J. Apostoli (Queen's University)H-Index: 4
#2Graham Skelhorne-Gross (Queen's University)H-Index: 4
Last. Christopher J. Nicol (Queen's University)H-Index: 14
view all 8 authors...
Breast cancer is the leading cause of new cancer diagnoses among women. Using peroxisome proliferator-activated receptor (PPAR)γ(+/−) mice, we showed normal expression of PPARγ was critical to stop 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast tumorigenesis. PPARγ is expressed in many breast cell types including mammary secretory epithelial (MSE) cells. MSEs proliferate as required during pregnancy, and undergo apoptosis or reversible transdifferentiation during involution once lactation ...
19 CitationsSource
#1Joanna HusznoH-Index: 5
#2Magdalena BudrykH-Index: 2
Last. Elżbieta NowaraH-Index: 6
view all 4 authors...
Objective: The presence of BRCA gene mutation and low expressions of BRCA proteins are associated with a greater sensitivity of tumor cells to
15 CitationsSource
#1Laoighse Mulrane (UCD: University College Dublin)H-Index: 8
#2Sharon F. McGee (UCD: University College Dublin)H-Index: 8
Last. Darran P. O'Connor (UCD: University College Dublin)H-Index: 24
view all 4 authors...
miRNAs have emerged, in the last decade, as key players in the carcinogenic process, with many candidates identified as playing important roles in many aspects of tumor development, growth, metastasis, and drug resistance. More recently, polymorphisms in miRNAs themselves or in their binding sites in target genes have been identified to incur increased risk of breast cancer in certain populations. In addition, epigenetic regulation and differential expression of processing enzymes has been shown...
109 CitationsSource
#1Jenni Nikkilä (The Breast Cancer Research Foundation)H-Index: 8
#2Ann Christin Parplys (UHH: University of Hamburg)H-Index: 5
Last. Robert Winqvist (OUH: Oulu University Hospital)H-Index: 46
view all 11 authors...
PALB2 is a BRCA1-/BRCA2-interacting protein and heterozygous mutations in PALB2 are associated with hereditary breast cancer predisposition. Here the authors show that human lymphoblastoid cells from heterozygous PALB2 mutation carriers display abnormal DNA replication dynamics and DNA damage response.
42 CitationsSource
#1Peter Bouwman (NKI-AVL: Netherlands Cancer Institute)H-Index: 19
#2Hanneke van der Gulden (NKI-AVL: Netherlands Cancer Institute)H-Index: 12
Last. Jos Jonkers (NKI-AVL: Netherlands Cancer Institute)H-Index: 61
view all 11 authors...
Mutations in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian cancers, and therefore sequence analysis of both genes is routinely conducted in patients with early-onset breast cancer. Besides mutations that clearly abolish protein function or are known to increase cancer risk, a large number of sequence variants of uncertain significance (VUS) have been identified. Although several functional assays for BRCA1 VUSs have been described, thus far it has not been possible to...
65 CitationsSource
#1Asher SalmonH-Index: 8
#2Mali Salmon-DivonH-Index: 20
Last. Tamar PeretzH-Index: 45
view all 7 authors...
Approximately 5% of all breast cancers can be attributed to an inherited mutation in one of two cancer susceptibility genes, BRCA1 and BRCA2 . We searched for genes that have the potential to distinguish healthy BRCA1 and BRCA2 mutation carriers from noncarriers based on differences in expression profiling. Using expression microarrays, we compared gene expression of irradiated lymphocytes from BRCA1 and BRCA2 mutation carriers versus control noncarriers. We identified 137 probe sets in BRCA1 ca...
6 CitationsSource
#1Graham Skelhorne-Gross (Queen's University)H-Index: 4
#2Alexis L. Reid (Queen's University)H-Index: 1
Last. Christopher J. Nicol (Queen's University)H-Index: 14
view all 10 authors...
19 CitationsSource
#1Rohini Roy (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
#2Jarin Chun (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 3
Last. Simon N. Powell (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 56
view all 3 authors...
The proteins encoded by the two major breast cancer susceptibility genes, BRCA1 and BRCA2, work in a common pathway of genome protection. However, the two proteins work at different stages in the DNA damage response (DDR) and in DNA repair. BRCA1 is a pleiotropic DDR protein that functions in both checkpoint activation and DNA repair, whereas BRCA2 is a mediator of the core mechanism of homologous recombination. The links between the two proteins are not well understood, but they must exist to e...
556 CitationsSource
Cited By15
#1Muthiah Bose (University of Oulu)H-Index: 1
#2Juliane Sachsenweger (University of Oulu)H-Index: 2
Last. Helmut Pospiech (University of Oulu)H-Index: 2
view all 20 authors...
Whilst heterozygous germline mutations in the ABRAXAS1 gene have been associated with a hereditary predisposition to breast cancer, their effect on promoting tumourigenesis at the cellular level has not been explored. Here, we demonstrate in patient-derived cells that the Finnish ABRAXAS1 founder mutation (c.1082G > A, Arg361Gln), even in the heterozygous state leads to decreased BRCA1 protein levels as well as reduced nuclear localization and foci formation of BRCA1 and CtIP. This causes distur...
1 CitationsSource
#1Shama Bhatia (U of T: University of Toronto)H-Index: 1
#2Danielle M. Drake (U of T: University of Toronto)H-Index: 2
Last. Peter G. Wells (U of T: University of Toronto)H-Index: 35
view all 4 authors...
1 CitationsSource
#2Carlos Benitez-Buelga (KI: Karolinska Institutet)H-Index: 4
Last. Ana OsorioH-Index: 43
view all 8 authors...
We thank the patients and healthy volunteers who participated in this study. We thank Dr Thomas Helleday (Karolinska Institutet, Stockholm, Sweden) for providingthe UNG enzyme. We thank all members of the Human Cancer Genetics Program of the Spanish National Cancer Research Centre for their support. JMB is supported by grant FPU15/01978 from the Spanish Ministry of Education, Culture, and Sport. CB-B is supported by the Spanish Ministry of Health FIS PI12/00070. This study was partially funded b...
1 CitationsSource
#1Danielle M. Drake (U of T: University of Toronto)H-Index: 2
#2Peter G. Wells (U of T: University of Toronto)H-Index: 35
#1Shoko Vos (UU: Utrecht University)H-Index: 4
#2Paul Joannes van Diest (UU: Utrecht University)H-Index: 3
Last. Cathy B. Moelans (UU: Utrecht University)H-Index: 19
view all 3 authors...
Abstract Background A considerable number of breast and ovarian carcinomas are due to underlying BRCA gene aberrations. Of these, BRCA germline mutations and BRCA promoter methylation are thought to be mutually exclusive, which could be exploited in clinical practice. However, this paradigm has not been studied extensively and systematically. Objective To systematically investigate to what extent BRCA promoter methylation has been reported in breast and ovarian carcinomas of BRCA germline mutati...
4 CitationsSource
#1Hiromi Tanaka (IU: Indiana University)H-Index: 9
#2Elizabeth A. Phipps (IU: Indiana University)H-Index: 2
Last. Brittney-Shea Herbert (IU: Indiana University)H-Index: 21
view all 9 authors...
1 CitationsSource
#1Jeroen Vierstraete (UGent: Ghent University)H-Index: 2
#2Andy Willaert (Ghent University Hospital)H-Index: 18
Last. Kathleen Claes (Ghent University Hospital)H-Index: 50
view all 6 authors...
Homologous Recombination (HR) repair is essential for repairing DNA double strand breaks (DSB) in dividing cells and preventing tumorigenesis. BRCA2 plays an important role in HR by recruiting the DNA recombinase RAD51 to the DSB. Despite being a popular model organism in genetic and cancer research, knowledge on the conservation of the HR pathway and function of zebrafish Brca2 is limited. To evaluate this, we developed a Rad51 foci assay in zebrafish embryos. We identified the zebrafish embryo...
2 CitationsSource
#1Joanne Kotsopoulos (U of T: University of Toronto)H-Index: 23
#2Karla Willows (U of T: University of Toronto)H-Index: 3
Last. T. May (Princess Margaret Cancer Centre)H-Index: 2
view all 9 authors...
Objective Women with an inherited BRCA1 or BRCA2 mutation may have an impaired ability to repair chemotherapy-induced damage as a result of a state of haploinsufficiency and may experience greater treatment-related toxicity. The objective of this study was to compare the hematologic adverse effect profiles associated with platinum-based chemotherapy in ovarian cancer patients with and without germline BRCA mutations. Methods We conducted a retrospective analysis of patients treated for high-grad...
3 CitationsSource
#1J. GayarreH-Index: 2
Last. María J. GarcíaH-Index: 24
view all 13 authors...
Despite a high prevalence of deleterious missense variants, most studies of RAD51C ovarian cancer susceptibility gene only provide in silico pathogenicity predictions of missense changes. We identified a novel deleterious RAD51C missense variant (p.Arg312Trp) in a high-risk family, and propose a criteria to prioritise RAD51C missense changes qualifying for functional analysis. To evaluate pathogenicity of p.Arg312Trp variant we used sequence homology, loss of heterozygosity (LOH) and segregation...
1 CitationsSource
#1Annelot Baert (UGent: Ghent University)H-Index: 6
#2Julie Depuydt (UGent: Ghent University)H-Index: 8
Last. Anne Vral (UGent: Ghent University)H-Index: 35
view all 13 authors...
Background Breast cancer risk increases drastically in individuals carrying a germline BRCA1 mutation. The exposure to ionizing radiation for diagnostic or therapeutic purposes of BRCA1 mutation carriers is counterintuitive, since BRCA1 is active in the DNA damage response pathway. The aim of this study was to investigate whether healthy BRCA1 mutations carriers demonstrate an increased radiosensitivity compared with healthy individuals.
9 CitationsSource